FDA Disclosures for Covid-19 Products Inconsistent, GAO Says

The FDA hasn’t been consistent with the safety and efficacy data it’s disclosed for authorized Covid-19 products and needs to beef up transparency with providers and the public, a federal watchdog said Tuesday.

The Government Accountability Office’s recommendations are aimed at improving public trust in the Food and Drug Administration during a time of wavering confidence in federal institutions’ ability to handle the pandemic.

The FDA authorized several virus therapies,"but the evidence to support its authorization decisions was not always transparent,” the GAO said in a new report. Those authorizations were for hydroxychloroquine in March, remdesivir in May, convalescent ...